| 1 |
29593217 | Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. | 2018 Mar 28 |
1 |
| 2 |
24967714 | Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity. | 2014 |
2 |
| 3 |
21945958 | Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. | 2011 Nov 8 |
1 |
| 4 |
18930512 | Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. | 2008 Dec 5 |
1 |
| 5 |
16912292 | Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. | 2006 Sep |
1 |
| 6 |
15767436 | Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan. | 2005 Apr |
1 |
| 7 |
15287381 | Demonstration of neutralizing mucosal IgA response to intranasal HIV-1 env DNA vaccines with or without the V3 glycosylation site. | 2004 |
1 |
| 8 |
8122371 | An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. | 1994 Mar |
1 |